关于贝利尤单抗治疗儿童狼疮性肾炎的一些个人见解

doi:10.12372/jcp.2025.24e0805

摘要/Abstract

摘要：

系统性红斑狼疮（systemic lupus erythematosus，SLE）是儿童最常见的系统性自身免疫性疾病之一，SLE累及肾脏即为狼疮性肾炎（lupus nephritis，LN），LN是影响 SLE 预后的重要因素之一。贝利尤单抗是一种针对B淋巴细胞刺激因子（BLyS）的重组人IgG1λ单克隆抗体，通过促进 B细胞凋亡从而抑制B细胞功能，可改善SLE的反应指数和疾病活动度评分，延缓LN的进展。笔者从儿科临床肾脏医师的角度，探讨了个人对贝利尤单抗治疗儿童LN的一些见解。

关键词: 系统性红斑狼疮, 狼疮性肾炎, 贝利尤单抗, 个人见解

Abstract:

Systemic lupus erythematosus (SLE) is one of the most common systemic autoimmune diseases in children. The involvement of the kidneys in systemic lupus erythematosus (SLE) is referred to as lupus nephritis (LN), which serves as a critical factor influencing the prognosis of SLE. Belimumab is a recombinant human IgG1λ monoclonal antibody targeting B-lymphocyte stimulator, which inhibits B cell function by promoting B cell apoptosis. Belimumab can improve the response index and disease activity score of SLE, and delay the progression of LN. As a clinical pediatric nephrologist, the author explores some personal advices on the treatment of LN in children with Belimumab.

Key words: systemic lupus erythematosus, lupus nephritis, belimumab, personal advice

张宏文. 关于贝利尤单抗治疗儿童狼疮性肾炎的一些个人见解[J]. 临床儿科杂志, 2025, 43(2): 147-149.

ZHANG Hongwen. Some personal advices on belimumab treatment in childhood lupus nephritis[J]. Journal of Clinical Pediatrics, 2025, 43(2): 147-149.

参考文献 20

[1]	Vazzana KM, Daga A, Goilav B, et al. Principles of pediatric lupus nephritis in a prospective contemporary multi-center cohort[J]. Lupus, 2021, 30(10): 1660-1670.
[2]	Levy RA, Gonzalez-Rivera T, Khamashta M, et al. 10 Years of belimumab experience: What have we learnt?[J]. Lupus, 2021, 30(11): 1705-1721.
[3]	Stohl W, Kwok A. Belimumab for the treatment of pediatric patients with lupus nephritis[J]. Expert Opin Biol Ther, 2023, 23(3): 243-251.
[4]	Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis[J]. N Engl J Med, 2020, 383(12): 1117-1128.
[5]	Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis[J]. Arthritis Rheumatol, 2021, 73(1): 121-131.
[6]	Rovin BH, Furie R, Teng YKO, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis[J]. Kidney Int, 2022, 101(2): 403-413.
[7]	Brunner HI, Abud-Mendoza C, Viola DO, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial[J]. Ann Rheum Dis, 2020, 79(10): 1340-1348. doi: 10.1136/annrheumdis-2020-217101 pmid: 32699034
[8]	Roberts JE, Burn C, Sadun RE, et al. Real-world use and outcomes of belimumab in childhood-onset lupus: a single-center retrospective study[J]. Lupus, 2023, 32(9): 1111-1116.
[9]	亚太医学生物免疫学会儿童过敏免疫风湿病分会(PAIRB-APAMBI)多中心研究协作组, 《中国实用儿科杂志》编辑委员会. 贝利尤单抗治疗中国儿童系统性红斑狼疮28周有效性和安全性分析: 一项回顾性多中心真实世界的初步研究[J]. 中国实用儿科杂志, 2021, 36(11): 858-868.
	Multi-center Research Collaboration Group, Pediatric Allergy Immunology Rheumatology Branchthe Asia-Pacific Association of Medicine and Bio-Immunology (PAIRB-APAMBI), Editorial Committee of Chinese Journal of Practical Pediatrics. Efficacy and safety analysis of belimumab for 28 weeks in real-world Chinese children with systemic lupus erythematosus: A retrospective multicenter pilot study[J]. Zhongguo Shiyong Erke Zazhi, 2021, 36(11): 858-868.
[10]	周涵, 梁伟, 丁国华. 贝利尤单抗在狼疮肾炎中的临床应用[J]. 临床肾脏病杂志, 2022, 22(10): 861-865.
	Zhou H, Liang W, Ding GH. Clinical application of belimumab in lupus nephritis[J]. Linchuang Shenzangbing Zazhi, 2022, 22(10): 861-865.
[11]	Pennesi M, Benvenuto S. Lupus nephritis in children: novel perspectives[J]. Medicina (Kaunas), 2023, 59(10): 1841.
[12]	陈元, 孔林笑语, 孙书珍, 等. 贝利尤单抗治疗儿童活动性狼疮性肾炎12例临床观察[J]. 中国小儿急救医学, 2022, 29(12): 981-984.
	Chen Y, Kong LXY, Sun SZ, et al. Clinical observation of belimumab in the treatment of 12 children with active lupus nephritis[J]. Zhongguo Xiaoer Jijiu Yixue, 2022, 29(12): 981-984.
[13]	檀晓华, 李彩凤, 赵文甲, 等. 贝利尤单抗治疗儿童难治性系统性红斑狼疮15例的疗效及预后随访研究[J]. 中华实用儿科临床杂志, 2022, 37(13): 983-987.
	Tan XH, Li CF, Zhao WJ, et al. Curative effect and follow-up analysis of 15 children with refractory systemic lupus erythematosus treated with Belimumab[J]. Zhonghua Shiyong Erke Linchuang Zazhi, 2022, 37(13): 983-987.
[14]	高雨彤, 何孝亮, 陈登环, 等. 贝利尤单抗治疗儿童系统性红斑狼疮17例临床疗效分析[J]. 临床儿科杂志, 2022, 40(10): 745-749.
	Gao YT, He XL, Chen DH, et al. Clinical effect of belizumab on 17 children with systemic lupus erythematosus[J]. Linchuang Erke Zazhi, 2022, 40(10): 745-749.
[15]	Tanaka Y, Bae SC, Bass D, et al. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea[J]. RMD Open, 2021, 7(2): e001629.
[16]	Wallace DJ, Ginzler EM, Merrill JT, et al. Safety and efficacy of Belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus[J]. Arthritis Rheumatol, 2019, 71(7): 1125-1134. doi: 10.1002/art.40861
[17]	Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS[J]. Kidney Int, 2024, 105(1S): S1-S69.
[18]	van Vollenhoven RF, Navarra SV, Levy RA, et al. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension[J]. Rheumatology (Oxford), 2020, 59(2): 281-291. doi: 10.1093/rheumatology/kez279 pmid: 31302695
[19]	Oni L, Wright RD, Marks S, et al. Kidney outcomes for children with lupus nephritis[J]. Pediatr Nephrol, 2021, 36(6): 1377-1385.
[20]	程程, 文思佳, 林知朗, 等. 儿童狼疮性肾炎的疗效及预后分析[J]. 中华儿科杂志, 2021, 59(9): 730-736.
	Cheng C, Wen SJ, Lin ZL, et al. Treatment effectiveness and long-term prognosis of childhood-onset lupus nephritis[J]. Zhonghua Erke Zazhi, 2021, 59(9): 730-736.